Pulsenmore Ltd.
For the period ended Jun 30, 2026. Filed Aug 31, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2026 · Filed Aug 31, 2026
Use the contents to explore the available documents and sections.
PLSM$1.51-2.6%Stored close · as of Nov 6, 2026
Contents
EX-99.3 · Product Development & Technology
Product Development & Technology
| ● | The Company supported FDA and AMAR submissions for the ES Tera product line (compatible for both iOS and Android devices). The Company received applicable regulatory clearances or authorizations for the ES Tera product line from the FDA and Israel’s Ministry of Health Medical Device Division, as applicable. |
| ● | Initial ES Tera production lots and first shipments to the U.S. market were completed. |
| ● | After the period ended June 30, 2026, in July 2026, the Company announced that it has been selected to participate in Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority and the Ministry of Health. As part of the program, the Company will lead a NIS 3 million (approximately $1 million) project in which the grant approved amounted to NIS 1.2 million (approximately $0.4 million). In August 2026, the Company announced that it received a second AI grant, after the Israel Innovation Authority approved NIS 3.8 million (approximately $1.27 Million) for the SmartScan AI Program. The second grant brings the total AI grants approved for the Company in the past months to NIS 5 million (approximately $1.67 million), supporting two programs with a combined scope of NIS 9.3 million approximately $3.12 million. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.